Cancer cells can undergo a metabolic reprogramming from oxidative phosphorylation to glycolysis that allows them to adapt to nutrient-poor microenvironments, thereby imposing a selection for aggressive variants. However, the mechanisms underlying this reprogramming are not fully understood. Using complementary approaches in validated cell lines and freshly obtained human specimens, we report here that mitochondrial respiration and oxidative phosphorylation are slowed in metastatic melanomas, even under normoxic conditions due to the persistence of a high nuclear expression of hypoxia-inducible factor-1a (HIF-1a). Pharmacologic or genetic blockades of the HIF-1a pathway decreased glycolysis and promoted mitochondrial respiration via specific reduction in the expression of pyruvate dehydrogenase kinase-3 (PDK3). Inhibiting PDK3 activity by dichloroacetate (DCA) or siRNA-mediated attenuation was sufficient to increase pyruvate dehydrogenase activity, oxidative phosphorylation, and mitochondrial reactive oxygen species generation. Notably, DCA potentiated the antitumor effects of elesclomol, a pro-oxidative drug currently in clinical development, both by limiting cell proliferation and promoting cell death. Interestingly, this combination was also effective against BRAF V600E-mutant melanoma cells that were resistant to the BRAF inhibitor vemurafenib. Cotreatment of melanomas with DCA and elesclomol in vivo achieved a more durable response than single agent alone. Our findings offer a preclinical validation of the HIF-1/PDK3 bioenergetic pathway as a new target for therapeutic intervention in metastatic melanoma, opening the door to innovative combinations that might eradicate this disease. Cancer Res; 72(19); 5035-47. Ó2012 AACR.
Introduction
Over the last decades, huge efforts devoted to comprehend melanoma biology led to the identification of new targets for antimelanoma therapy (1) . Apart from targeting the oncogenic mutations present in many (but certainly not all) melamomas, another promising strategy is to exploit biochemical particularities of melanoma cells. One biochemical hallmark of melanoma is the generation of excessive reactive oxygen species (ROS; refs. 2, 3) . It is generally postulated that the cellular effects of ROS depend on the level at which ROS are produced. Controlled production of ROS participates in the promotion and progression of melanoma (3), whereas higher ROS generation displays cell-damaging effects (4) . Constitutive production of the ROS weakens melanoma cells that are closer to the point where cell death can occur. Hence, melanoma cells show increased sensitivity to ROS-induced death as compared with melanocytes and to other tumors (5) . According to this view, elesclomol, a pro-oxidant molecule that targets the mitochondrial electron transport chain (ETC; ref. 6 ), has been evaluated in clinical trials for the treatment of metastatic melanomas and has shown encouraging clinical responses. Intriguingly, clinical favorable responses occurred in a subset of patients distinguished by low serum lactate dehydrogenase (LDH; ref. 7) . Thus, serum LDH can be considered as the predictor of response to elesclomol. At a cellular level, elesclomol requires a functioning ETC to induce ROS-mediated melanoma cell death (6) . In this context, unraveling the regulatory mechanisms essential for enhancing ROS production is fundamental for improving the efficiency of pro-oxidants in melanoma.
Approximately, 60% to 90% of cancers display a metabolic profile, the so-called Warburg phenotype, characterized by their dependence upon glycolysis as the major source of energy, irrespective of the oxygen level (8) . According to the Warburg effect, pyruvate, the end product of glycolysis, is mainly converted into lactate by LDH-A that is upregulated in transformed cells, rather than oxidized in mitochondria.
It seems conceivable that melanoma cells mainly rely on glycolysis for energetic needs based on the following reasons: (i) the glycolytic phenotype of melanoma cell lines has been recently identified by metabolic profiling (9) ; (ii) metastatic melanomas are characterized by their particularly high avidity for 2[18F]fluoro-2-deoxy-D-glucose ( 18 FDG) clinically detectable on positron emission tomography (PET; ref. 10); (iii) the isoenzyme LDH-5, the more effective in the conversion of pyruvate to lactate, is detected on histologic sections and in blood sera from patients with highly metastatic melanoma (for review; ref. 11); and (iv) hypoxia-inducible factor-1a (HIF-1a), a master regulator of metabolism required for the active adaptation of cancer cells to hypoxic conditions, is overexpressed in human melanoma (12, 13) . In addition to hypoxia, HIF-1a has also been found stabilized in normoxic conditions in melanoma cells. For instance, melanoma antigen-11 regulates HIF-1 accumulation by inhibition of prolyl hydroxylase activity (14) . Endothelin or the antiapoptotic protein, Bcl-2, induces HIF-1a accumulation (15, 16) . Genetic alterations, such as Microphthalmia-Associated Transcription Factor (MITF) germline mutation (17) or the oncogenic V600E BRAF mutation (18) overexpress HIF-1a and enhance transcriptional activity of downstream genes.
However, recent studies indicate that melanomas do not adopt a bona fide Warburg phenotype, as glutamine stimulates mitochondrial metabolism to favor melanoma growth (9, 19) . It is well established that, under hypoxic conditions, HIF-1a activates the expression of glycolytic enzymes and glucose transporters and downregulates mitochondrial activity and ROS production through several distinct mechanisms in a context-specific manner (20) . HIF-1a has also been involved in the "glutamine addiction" of cancer cells (21) .
Our objective was to investigate the influence of metabolic pathways on mitochondrial ROS production, particularly in melanoma under normoxic conditions. We hypothesized that HIF-1a can also prevent the onset of oxidative stress via downregulation of mitochondrial respiration, and therefore can itself represent a factor of resistance to pro-oxidative drugs in melanomas.
Materials and Methods

Chemicals
All chemicals were purchased from Sigma-Aldrich except CM-H 2 DCFDA from Life Technologies and YC-1) from Cayman Chemical Company (Interchim). Elesclomol, provided by Synta Pharmaceuticals Corp., was prepared as described (6) . The combined effect of dichloroacetate (DCA) and elesclomol was analyzed by the combination index isobologram (22) .
Patients and tissue samples
Cutaneous metastases were obtained from 4 melanoma patients (see Supplementary Table S1 ) at the Clinique de Dermatologie, CHRU (Lille, France). Ethical approval for this study was obtained from the local Person's Protection Committee, and all patients provided informed consent. The samples came from patients who had to be treated surgically for cutaneous melanoma metastases.
Cell lines
HL60, A375, and SKMel-28 were obtained from American Type Culture Collection over the past 2 years. The human melanoma cell lines HBL, LND, MM074, and MM079 were established in the Laboratory of Oncology and Experimental Surgery (Institut Bordet, Universit e libre de Bruxelles, Brussels, Belgium) from lymph node metastases of patients with melanoma and were kindly provided by G. Ghanem in 2009. Mel-4M was established in the laboratory by Dr. Polakowska in 2009. All cells were passaged within 6 months of thawing. The identity of cell lines was regularly examined by morphologic criteria and the presence of differentiation markers (last test in March 2012). They were expressing at least one of the melanocyte differentiation markers (TYR, TYRP1, TYRP2/DCT, Melan-A/MART-1, gp100/pmel17, S100B) as routinely assessed by Western blotting/immunofluorescence. The identity of HBL, LND, and Mel-4M was also confirmed by karyotyping and array comparative genomic hybridization testing (IRCL and Laboratoire de g en etique, CHRU, Lille, France).
All cell lines were cultured at 37 C under 5% CO 2 in RPMI medium (Gibco-BRL, Life Technologies) supplemented with 10% fetal calf serum (Gibco-BRL), antibiotics, and 1 mmol/L sodium pyruvate (Gibco-BRL). Cells were transfected with siRNA targeting PDK-3 (sc-39029, Santa Cruz Biotechnology) or a nontargeting control siRNA (sc-37707) using Lipofectamine 2000 (Life Technologies). PDK3 overexpression in melanoma cell lines was obtained by transfection with pJP1520-PDK3 vector [provided through central repository DNASU (http://dnasu.asu.edu; ref. 23 )] DCA, and/or elesclomol were added 48 hours after transfection. HBL cells lacking mitochondrial DNA (HBL r 0 ) were generated as published (24) . The A375 cell line, which harbors the BRAFV600E mutation, was treated with vemurafenib to obtain the resistant subline (A375-R) as described in the Supplementary material.
HIF-1a shRNA
Three HIF-1a short hairpin RNA (shRNA) clones (see Supplementary material for sequences) were obtained by limiting dilution. Activation of HIF-1a was quantified by a DNA-binding ELISA kit (TransAM Active Motif).
Determination of glucose, lactate, and ATP Extracellular glucose and lactate levels were measured on a SYNCHRON LX20 Clinical system (Beckman Coulter). For assessment of intracellular ATP, the Celltiter Glow Assay Kit (Promega) was used.
Cytofluorometric analysis
Cell viability and cell cycle were assessed after staining with propidium iodide (PI). The detection of ROS was determined using the CM-H 2 DCFDA or hydroethidium probe following current protocols (25) and conducted on a FACS Canto II cytofluorometer (Beckton Dickinson). Figure 1 . A, colony-forming assays of cells in the presence of glucose or glutamine (mean AE SD; n ¼ 3, t-test, ÃÃ , P < 0.01). B, cell-cycle analysis of cell lines treated with 10 mg/mL oligomycin, 5 mmol/L rotenone, or 75 mmol/L bromopyruvate for 24 hours. Numbers represent the percentage of sub-G1 cells. C, cells were treated with oligomycin for 4 hours then collected for ATP measurement (mean AE SD, n ¼ 3). D, growing, the rate of glucose and lactate released by cells (0.9 Â 10 6 cells/mL) in RPMI medium was calculated by dividing the difference of amount of glucose/lactate present in the supernatant between the 2 consecutive time points (2-6 hours) by the number of hours elapsed (mean AE SD, n ¼ 5). E, oxygen consumption of intact cells. Data are representative of 5 experiments. F, proportions of mitochondrial oxygen consumption due to proton leak (respiration not modified by oligomycin) and ATP turnover (the respiration inhibited by oligomycin). Oxygen consumption was determined as in E (mean AE SD, n ¼ 3 Fig. 1D . J, proportion of OXPHOS-related respiration was obtained by the difference between routine and oligomycin-inhibited respirations normalized with maximum mitochondrial respiratory capacity. ATP levels were also determined (mean AE SD, n ¼ 5).
PCR analysis
The mRNA was quantified by quantitative real-time PCR using a protocol optimized for Lightcycler 480 detector (Roche Applied Science; ref. 25) . The primer sequences are available upon request. The transcript level in each sample was normalized to that of 18S rRNA. The relative expression of target mRNAs was analyzed using the Pfafll method (25) .
Metabolite profiles
Metabolites were extracted (26) , and profiles were obtained using the 1 H-NMR method as previously described (25) .
Immunoblot analysis
Immunoblotting was conducted as indicated (25) . To detect ETC proteins, monoclonal antibodies (OXPHOS complexes kit, MitoSciences; 1:1,000) were used. Otherwise, the primary antibodies used are described in Supplementary materials.
Chromatin immunoprecipitation
Cells were cross-linked in 1% formaldehyde for 8 minutes and processed for chromatin immunoprecipitation (ChIP) assay using the HIF-1a ExactaChIP Chromatin IP Kit (R&D Systems). Capture of the DNA fragments was tested by PCR using PDK3 primers previously reported (27) .
Measurement of oxygen consumption
Oxygen consumption was monitored with Oxygraph oxygen electrodes (Hansatech Instruments Ltd.; ref. 25) . Cell viability was checked by PI staining. For melanoma specimens, oxygen consumption assays were conducted using the respirometry system Oxygraph-2k (Oroboros Instruments). Data were normalized to the dry weight of the specimens.
PDH activity and phosphoPDH detection
The determination of pyruvate dehydrogenase (PDH) activity and phosphorylation of PDH were conducted using the PDH Assay Kit (MSP18, Mitosciences) and the PhosphoPDH In-Cell ELISA Kit Colorimetric (MSP48, Mitosciences), respectively.
Transmission electron microscopy
Cells were prepared for transmission electron microscopy as described (25) .
Histology
Tumor specimens were stained with H&E. For in situ determination of cell proliferation or apoptosis, sections were analyzed with an antibody to Ki-67 or terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL; In Situ Cell Death Detection Kit, Roche). As a marker of ROSmediated protein oxidation, protein carbonyls were detected by the dinitrophenyl hydrazine (DNPH) method using Oxyblot Protein Oxidation Detection Kit (Millipore).
In vivo study
All procedures with animals were conducted according to the Institutional guidelines. Immunodeficient female severe combined immunodeficient (SCID) mice, 6-to 8-week-old, under isoflurane anesthesia were injected with 2 Â 10 6 HBL cells, mixed (1:1 volume) with BD Matrigel Basement Membrane Matrix. When tumors reached 400 mL, the mice were divided into 4 groups: control group (n ¼ 4): mice were treated with saline with the same schedule as the treated animals; elesclomol group (n ¼ 6): mice were treated with elesclomol (20 mg/kg, i.v. injection for 5 d/wk); DCA group (n ¼ 6): mice were treated with DCA (75 mg/L added to the drinking water); DCA/ elesclomol group (n ¼ 6) mice were treated with the combination of DCA and elesclomol. For patients' tumors implanted in mice, fresh tumor samples were minced into small pieces, mixed (1:1 volume) with Matrigel, and then injected into the flank of SCID mice as described earlier.
Imaging microPET scan analysis
The PET experiments (authorization N 14-55) were carried out under anesthesia. Images were acquired on a microPET Siemens Inveon Preclinical system. The emission scan lasting 1 hour was initiated after injection of 18 FDG (%370 MBq/kg) through the tail vein. To quantify the 18 F-FDG uptake on the last frame (corresponding to 40-60 min), the measured tissue activity concentration [counts (kBq)/mL] was divided by the injected activity in kBq per gram of body weight (kBq/g) to give a standardized uptake value (SUV).
Statistical analysis
Results were analyzed using GraphPad Prism version 5.00 (GraphPad Software). The Student t test was used to compare data sets. Statistical significance was set at P < 0.05. Figure 3 . A, schematic overview of pyruvate oxidation in mitochondria with inhibitors used in this study. B, mRNA expression levels of PDK1-4 isoforms. C, protein expression levels of PDK3. D, ChIP assay in HBL cells kept in normoxia or treated with 500 mmol/L DFO for 18 hours. HBL kd2 served as control. Reaction controls used nonspecific IgG antibodies and PCR conducted by using whole genomic DNA (input). Captured DNA was analyzed by PCR using
Results
Metabolic signature of metastatic melanoma cells
We first examined the effects of glucose and glutamine shortage on cell growth. In low glucose medium, HBL cells dramatically reduced their ability to proliferate. The absence of glutamine also limited HBL cell growth (Fig. 1A) . Moreover, melanoma cells were partially resistant to cell death induced by the mitochondrial inhibitors (rotenone or oligomycin), whereas maximum cell death was achieved when cells were incubated with bromopyruvate to inhibit glycolysis. Conversely, the promyelocytic cell line, HL60, was critically dependent on OXPHOS for survival [ Fig. 1B and (28, 29) ]. All melanoma cell lines studied had a cell death profile similar to that of mitochondrial DNA-depleted melanoma cells (HBL r 0 ), which lack functional ETC (24) . Inhibition of ATP synthase with oligomycin had almost no impact on ATP in melanoma cells, whereas in HL60, ATP level was highly sensitive to inhibition by oligomycin (Fig. 1C) . Thus, metastatic melanoma cells, such as respiratory deficient r 0 cells, generate almost all ATP via glycolysis despite abundant oxygen, a situation known as the Warburg effect (30) . Confirming this phenotype, a high glycolytic activity as measured by glucose consumption and lactate production characterized melanoma cells (Fig. 1D) . Melanoma cell lines also exhibited a significantly lower oxygen consumption rate than HL60 (Fig. 1E) . Moreover, the proportion of melanoma respiration used to produce ATP (ATP turnover) was far less important than that of HL60 (Fig. 1F) . These results were confirmed in metastatic melanoma specimens from patients (see Supplementary Table S1 and Supplementary Fig.  S1A ) compared with the surrounding tissues ( Fig. 1G and H) . Finally, we evaluated oxygen consumption in melanoma cells isolated from cutaneous metastasis (patient 2) according to the intensity of 18 FDG uptake, expressed as SUVs (Fig. 1I) . Specimen taken from high-SUV area (inner zone) showed weak respiration rate and low ATP turnover as compared with peripheral specimen from low SUV area (Fig. 1I) . Thus, the metabolic phenotype of human melanoma is characterized by high rates of aerobic glycolysis, dependence on glutamine, and low mitochondrial activity.
HIF-1a is critical for the metabolic phenotype of metastatic melanoma
As HIF-1 is a critical regulator of metabolism in cells under hypoxic conditions (31), we studied the role of HIF-1a in melanoma cells maintained in normoxia. Confirming previous data (12, 32), HIF-1a was expressed under normoxia in nuclei of melanoma cells (Fig 2A and B and Supplementary Fig. S1B ) and of metastatic melanomas from patients ( Supplementary  Fig. S1A ). The influence of hypoxia on selective HIF-1a expression was moderate [ Fig. 2A and ref. (32) ]. We then used shRNA targeting HIF-1a mRNA for knockdown of gene expression ( Supplementary Fig. S1C and S1D and Fig. 2B ) in the HBL cell line selected for its elevated level of HIF-1a ( Fig. 2A and B) . HIF1a knockdown cells resulted in significant decreased expression of key glycolytic genes and corresponding proteins, such as hexokinase II, the first step rate-limiting enzyme of glycolysis and LDH-A, which converts pyruvate into lactate, the final product of glycolysis ( Fig. 2C and D) . In addition, a prominent decrease in lactate release was observed in shRNA cells (Fig. 2E) , and HIF-1a knockdown cells were relatively resistant to death induced by the glycolytic inhibitor, 2-DG (Fig. 2F) . Comparison of 18 FDG accumulation in tumor xenografts showed a sharply higher activity in control cells compared with HIF-1a knockdown cells supporting the crucial role of HIF-1a in the glucose addiction of melanoma (Fig. 2G) . Moreover, HIF-1a knockdown cells were resistant to the antiproliferative effect of glutamine shortage (Fig. 2H) suggesting that HIF-1a also contributes to the dependence of melanoma cells on glutamine. In comparison with control cells, HBL cells lacking HIF-1a showed a 2-fold increase in mitochondrial oxygen consumption (Fig. 2I and Supplementary Fig. S2A ). Similar mitochondrial effects were observed when cells were incubated with YC-1 (Fig. 2I) , an established HIF-1a inhibitor (ref. 33 and Fig. 2B ). Relative to HBL scrambled cells, HIF-1a shRNA cells presented significantly higher levels of tricarboxylic acid (TCA) intermediates, accumulation of glutamine, and lower contents of intracellular lactate as quantified by 1 H-NMR (Table 1) . Derepression of mitochondrial respiration in cells lacking HIF-1a significantly enhanced the fraction of respiration that is used for ATP synthesis, and therefore they produced more ATP than scrambled shRNA cells (Fig. 2J) . By accomplishing these major effects on glycolysis, glutamine metabolism, and mitochondrial respiration, HIF-1a drives the main metabolic changes observed in melanoma.
A HIF-1a-dependent PDK3 pathway controls mitochondrial respiration
We then evaluated the mechanisms by which HIF-1a downregulates mitochondrial OXPHOS. We found no change in the shape and number of mitochondria ( Supplementary Fig. S2B-S2D ). Unlike previous description (34), the respiratory chain primers specific for PDK3. E, PDH activity was determined as described in Materials and Methods. Data are representative microplate-recorded data from 3 experiments. F, HBL cells treated with DCA for 4 hours and HBL HIF-1a shRNA cells were tested in cell-ELISA kit or immunoblotted to detect phosphorylated PDH and total PDHEA1a. Results are expressed as percentage of control (untreated) HBL cells (mean AE SD, n ¼ 3; Ã , P < 0.05 and ÃÃ , P < 0.01). G, respiration rates of HBL (without glutamine), HBLr0, and HL-60 cells treated with DCA for 15 minutes (left) or in PDK3 siRNA HBL cells (right). Bottom, HBL cells were transiently transfected with empty vector (Mock) or full-length human PDK3 cDNA (PDK3) and respiration was assessed as in Fig. 1E in cells treated with 5 mmol/L DCA for 30 minutes. H, mitochondrial respiration in tissues from HBL tumor-bearing mice was assessed as in Fig. 1G following ex vivo addition of DCA (1.2 mmol/L every 3 minutes, arrows). I, respiration rate in melanoma metastasis to the skin (black) and peritumoral tissue samples (white) from patient 1 following the sequential addition of DCA (0.6 mmol/L, arrows). J, partial 1 H-NMR spectra of aqueous extracts from HBL cells treated with DCA. Results showed a 38% AE 24% increase for fumarate (Fum), 42% AE 7% for malate (~), 40% AE10% for succinate (Succ), 36% AE 8% for citrate ( * ), 105% AE 12% for glutamate (Glu), and 68% AE 18% for glutamine (Gln) in DCA-treated HBL cells compared with untreated cells. Spectra are representative of 10 experiments. K, HBL cells were treated with DCA for 18 hours, then the nuclear/cytosolic fractions were subjected to immunoblotting for HIF-1a or LDH-A.
complex IV and the expression of ETC proteins were not affected by HIF-1a expression ( Supplementary Fig. S2E and  S2F ). Four different PDH kinases (PDK1-4) are known to phosphorylate the E1 moiety of the PDH complex (PDH) at 3 serine sites, thereby decreasing PDH activity and preventing pyruvate from undergoing mitochondrial oxidation [ Fig. 3A  and ref. (35) ]. HIF-1a knockdown correlated with the reduced expression of PDK3 mRNA without significantly affecting the related isoforms (Fig. 3B) . Results were confirmed at the protein level (Fig. 3C and Supplementary Fig. S1B ). Chromatin immunoprecipitation assay showed the direct binding of HIF1a to the PDK3 promoter in living cells (Fig. 3D) . In agreement with the aforementioned data on PDK3 downregulation, PDH activity was enhanced in HIF-1a knockdown cells or in melanoma cells incubated in the presence of YC-1 ( Fig. 3E and Supplementary Fig. S3 ). Increased PDH activity was also observed in cells transfected with siRNA directed against PDK3 or in the presence of the pyruvate dehydrogenase kinase (PDK) inhibitor, DCA ( Fig. 3E and Supplementary Fig. S3 ). Dephosphorylation of PDH in HIF-1a knockdown cells or in HBL cells treated with DCA (Fig. 3F ) correlated with the activation of PDH.
Accordingly, exposure of HBL cells (Fig. 3G) , HBL tumors from SCID mice (Fig. 3H) , or freshly resected cutaneous metastases (Fig. 3I) to DCA resulted in a dose-dependent increase of mitochondrial respiration regardless of the presence or absence of glutamine (Fig. 3G) . No such effects were observed in HBL r 0 cells or in the OXPHOS-dependent cell line HL60 (Fig. 3G, top left) . DCA-induced increase in respiration was abolished by overexpression of PDK3 (Fig. 3G, bottom) suggesting that PDK3 is an important target for DCA. Moreover, DCA decreased the nuclear level of HIF-1a as well as its target LDH-A (Fig. 3K) . There was a similar trend toward increased mitochondrial respiration in melanoma cells transfected with PDK3 siRNA (Fig. 3G, top right) , comparable with that observed for cells lacking HIF-1a (Fig. 2I ). We noted a significant elevation in several TCA cycle intermediates, glutamine, and a low lactate content in DCA-treated cells (Fig. 3J ) mirroring the phenotype observed in HIF-1a kd cells (Table 1) . Thus, a HIF-1a/PDK3 axis contributes to the control of mitochondrial respiration observed in melanoma.
Inhibition of the HIF-1a-dependent PDK3 pathway enhances mitochondrial ROS generation
We next decided to investigate whether the enhanced mitochondrial respiration would lead to increased mitochondrial ROS generation. We observed a significant increase in the ROS levels when PDK3 activity was inhibited by siRNA or DCA ( Fig. 4A and Supplementary Fig. S4 ). Incubating PDK3 siRNAor DCA-treated HBL cells with distinct ROS inducers further increased ROS levels. The pro-oxidative effect of DCA was maintained after glutamine withdrawal (Fig. 4A) . Remarkably, DCA had no additional effect on ROS production in PDK3 siRNA knockdown cells, and PDK3 overexpression impeded DCA-induced increase in ROS generation confirming PDK3 as a potential target for DCA (Fig. 4B) . Consistently, exposure of cells lacking HIF-1a to the ROS inducers also generated more ROS than cells expressing HIF-1a ( Fig. 4C and Supplementary   Fig. S4 ). In the r 0 clone, due to its lack of basal (Fig. 1E ) and DCA-induced respiration (Fig. 3G) , the pro-oxidant capacities of DCA were markedly diminished compared with HBL parental cells (Fig. 4D) . The complex I inhibitor, rotenone, dramatically decreased DCA-induced ROS generation in the same manner as the classic antioxidants, vitamin C and N-acetyl cysteine (NAC; Fig. 4E ). It must be noted that apocynin, a classic inhibitor of NADPH oxidase, which has also predominant antioxidant capacities (36), reduced DCA-stimulated ROS production with about 40% ROS inhibition. The inhibitor of complex III, antimycin A, also reduced ROS production when combined with DCA, whereas the complex IV and V inhibitors had no noticeable effects (Fig. 4E) . This would indicate that mitochondrial ROS promoted by DCA originated from complex I and/or III. Altogether, our results suggest that the HIF1a/PDK3 axis protects melanoma from mitochondrial ROS production.
Inhibition of the PDK3-dependent HIF-1a pathway promotes antimelanoma activity of elesclomol Finally, we investigated whether mitochondrial ROS generation promoted by DCA and elesclomol had potent antimelanoma activities. The combination of DCA and elesclomol inhibited cell viability more than each treatment did alone (Fig. 5A-C and Supplementary Fig. S5 ). In congruence with these findings, PDK3 inhibition rendered HBL cells highly sensitive to elesclomol-induced cell death (Supplementary Fig.  S5 ). Selected concentration curves indicate a synergistic effect for HBL cells when DCA was combined with elesclomol ( Fig.  5A) . Interestingly, combination of DCA and elesclomol was sufficient to induce oxidative cell death in A375 melanoma cells with acquired resistance to vemurafenib (Fig. 5D) .
To explore the therapeutic usefulness of pharmacologic combination, we sought to determine whether DCA treatment sensitized HBL xenografts to elesclomol in vivo. DCA or elesclomol alone reduced growth of HBL xenografts (Fig. 5E ). In comparison, the combination of DCA and elesclomol was more effective in delaying tumor growth than single agent alone. Very similar results were obtained in a preclinical model consisting to evaluate the response of human tumor fragments grafted into SCID mice to drug combination (Fig. 5F ). Treatment of mice with the combination of DCA and elesclomol was more effective in accumulating oxidatively modified proteins, reducing cell proliferation, and inducing apoptosis of HBL xenografts than single agent alone (Fig. 5G) . Altogether, these data suggest that the antimelanoma activity of elesclomol, although effective alone, can be significantly enhanced by DCA.
Discussion
Our results show that melanoma cells use mainly glycolysis, and not mitochondria, for energy production and cell proliferation. In agreement with other reports (9, 19), we observed that glutamine also supports melanoma cell growth. Glucose and glutamine metabolic pathways are able to compensate from one another to promote cancer cell survival (37, 38) . However, unlike the model originally stipulated by Warburg (39) , melanoma cells maintain functional mitochondria. Thus, Ã or #, P < 0.05 and ## or ÃÃ , P < 0.01. D, effects of the combination DCA þ elesclomol on vemurafenib-resistant melanoma cells. The A375 parental cell line and the A375-R vemurafenib-resistant cells were exposed to 1 mmol/L DCA and/or 300 nmol/L elesclomol for 8 hours or 300 nmol/L vemurafenib for 48 hours and submitted to CM-H 2 DCFDA staining. The gray peak represents cells not exposed to drugs. Numbers refer to the percentage of cell death determined by PI staining cells from parallel culture. E, the tumor-bearing mice were divided into 4 treatment groups: control, DCA alone, elesclomol alone, or the combination of elesclomol and DCA (mean AE SD, n ¼ 4 to 6) Ã , P < 0.05. F, xenografted tumor fragments from patient 1 were treated (indicated by arrow) following the protocol described in E. G, sections from the tumors of HBL-injected mice were stained with an antidiphenylhydrazine antibody for detection of carbonylated proteins as a marker of irreversible oxidative damage, with an antiKi67 antibody to assess proliferation and by TUNEL assay to detect apoptotic cell death. Insert corresponds to positive control for TUNEL (mean AE SD, n ¼ 4, Ã , P < 0.05 vs. control).
we showed that inhibition of the HIF-1a/PDK3 axis is able to restore respiration in mitochondria of melanoma cells. These findings confirm that cancer cells possess a highly adaptable metabolism. Reduction in LDH-A activity (40) causes derepression of mitochondrial respiration (25) . Inhibition of PDK favors mitochondrial oxidation and ROS production in lung carcinoma (41) . Forced oxidative metabolism interferes with tumor cells proliferation and survival (25, 40, 41) . Thereby, the metabolic flexibility of cancer cells creates a new perspective for the development of therapeutic approaches. HIF-1a has been found highly expressed in melanoma cells kept under normoxic conditions (12, 32) . The elevated expression of HIF-1a is correlated with the advanced stage of melanoma (12) . Our results are consistent with the view that melanoma progression is associated with the apparition of changes in mitochondrial metabolism in a HIF-1a dependent manner. Conversely, nonmetastatic primary melanomas upregulate genes involved in mitochondrial oxidative phosphorylation (42) .
Our study defines the HIF-1a/PDK3 axis as a sensor for metabolic stress that regulates mitochondrial ROS level under normoxia. Overexpression of HIF-1a reduces the basal level of ROS in hypoxic cancer cells (43) . The isoenzyme PDK3 is expressed in several cancer cells, such as neuroblastoma, colon cancer (27) , or leukemia (25) . Hypoxic activation of the PDK3-dependent HIF-1a pathway has been previously involved in tumor progression and drug resistance (27) . In agreement with our findings, the transcription profiling of human cancer cell lines confirmed the high expression of PDK3 in melanomas (deposited in Array Express database, accession number E-MTAB-37). PDK3 is the only isoform reported to be not inhibited by a high concentration of pyruvate (44) . Interestingly, high pyruvate and lactate concentrations result in nonhypoxic HIF-1a stabilization (45) . Thus, as suggested (45), HIF-1a-mediated PDK3 expression may favor HIF-1a stabilization independently of hypoxia in a self-amplifying loop that contributes to locking the melanoma cell metabolism into aerobic glycolysis.
Our findings provide an attractive explanation for the predictive value of LDH in patients treated with elesclomol (7). Because LDH-A is transcriptionally regulated by HIF-1a ( Fig.  2C and D) , serum LDH may be considered as an indirect marker of the HIF-1a-mediated defective mitochondrial activity. In that way, we propose that tumors from patients with high LDH levels have also inactive mitochondria, a situation that we found associated with resistance to elesclomolinduced cell death in vitro (6) . Under such conditions, inhibition of HIF-1a and LDH expression by DCA (Fig. 3K) can contribute to restore sensitivity to elesclomol. Finally, we have shown that combined inhibitors of the HIF-1a/PDK3 axis along with pro-oxidant drugs have potential antimelanoma capacities. The hypoxia-independent activation of HIF-1a, found in certain metastatic melanomas (such as those with activation of the MITF pathway or harboring BRAF mutation), would confer particular sensitivity to this drug combination. Thus, in line with our results, this new therapeutic approach would be likely beneficial to patients progressing on BRAF inhibitors.
To best translate in vitro results into clinical application, we have chosen the combination of existing drugs (DCA and elesclomol) that are already in the clinic. Elesclomol is one of the first mitochondrial-targeted drugs that has recently entered the clinical trials (7). Elesclomol does not act by specific targeting of mitochondrial proteins but most likely by interfering with the electron flow to promote mitochondrial ROS production (6). Thus, we have shown that the DCA-dependent enhancement of the electron flow impaired by elesclomol results in huge production of ROS. DCA, previously used to treat mitochondrial diseases without major toxicity, is currently undergoing clinical evaluation for cancer (46) . DCA irreversibly inhibits all PDK isoenzymes (47) . We have shown that knocking down HIF-1a markedly reduced PDK3 expression but not other isoenzymes under normoxic conditions (Fig. 3B) . However, both PDK1 and PDK3 were upregulated under hypoxic conditions (not shown), and it has been proven that PDK1 prevents the overproduction of mitochondrial ROS in response to hypoxia (48, 49) . Because solid tumors consist of both normoxic and hypoxic regions, the use of a broadspectrum inhibitor of all 4 PDK isoenzymes, such as DCA, is of particular interest in vivo to fully reactivate mitochondria. However, the main disadvantage of DCA, when used alone, is that its in vivo antitumor activity is only apparent at high concentrations (46) . Our results suggest that DCA can be also used in combination regimen to boost the mitochondrial electron flux and then potentiate the antitumor activity of pro-oxidant drugs, such as elesclomol. Thus, our results offer proof-of-concept for using elesclomol combined with DCA against metastatic melanoma including those who have become resistant to BRAF inhibitors. In conclusion, inactivation of the HIF-1a/PDK3 axis presents new therapeutic opportunities against metastatic melanoma.
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